Danon Disease Medication

  • Author: Christopher C Erickson, MD; Chief Editor: Bruce Buehler, MD   more...
 
Updated: Jan 6, 2010
 

Medication Summary

No cardiac medications resolve the problem of hypertrophic cardiomyopathy (HCM), particularly in Danon disease. However, standard medications for congestive heart failure (CHF) and arrhythmias should be used as they are in other patients with these conditions. For Danon disease with HCM, no medical treatment is indicated unless the patient has symptoms of CHF or angina. On the contrary, patients with dilated cardiomyopathy should be given anti-CHF medications.

No medications are known to resolve or ease the neuromuscular symptoms of Danon disease.

To the authors' knowledge, no reports have demonstrated successful experience with any of the antiarrhythmic agents used in Danon disease. However, treatment of supraventricular tachycardia (SVT) should begin with beta-blockers. Digoxin and verapamil should be avoided when evidence suggests the presence of Wolff-Parkinson-White syndrome. Although ablation may be indicated, other antiarrhythmic medications (eg, propafenone, disopyramide, amiodarone, sotalol) may be helpful to control SVT if ablation is not possible or desired. The beneficial effects or adverse effects of these medications, when used in Danon disease, have not been established.

Next

Diuretic agents

Class Summary

These drugs are indicated for CHF due to systolic or diastolic dysfunction.

View full drug information

Furosemide (Lasix)

 

Loop diuretic that increases excretion of water by interfering with chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Increases renal blood flow without increasing filtration rate. Onset of action generally within 1-h. Increases potassium, sodium, calcium, and magnesium excretion.

Dose must be individualized to patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after previous dose, until desired diuresis occurs. In infants, titrate with 1-mg/kg/dose increments until satisfactory effect achieved.

Diuretics have major clinical uses in managing disorders involving abnormal fluid retention (edema) or in treating hypertension; diuretic action decreases blood volume.

PO administration less potent diuretic effect than IV administration.

View full drug information

Spironolactone (Aldactone)

 

Potassium-sparing diuretic. Indicated for management of edema resulting from excessive aldosterone excretion. Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions.

Previous
Next

Beta blockers

Class Summary

These agents are indicated for the management of dilated cardiomyopathy.

View full drug information

Carvedilol (Coreg)

 

Used only for patients with dilated cardiomyopathy and CHF. Nonselective beta- and alpha-adrenergic blocker. Also has antioxidant properties. Does not appear to have intrinsic sympathomimetic activity. May reduce cardiac output and decrease peripheral vascular resistance.

View full drug information

Metoprolol (Lopressor)

 

Indicated for dilated cardiomyopathy. Selective beta1-adrenergic receptor blocker that decreases automaticity of contractions.

Previous
Next

ACE inhibitors

Class Summary

These agents reduce afterload in dilated cardiomyopathy and/or CHF.

View full drug information

Enalapril (Vasotec)

 

Prevents conversion of angiotensin I to angiotensin II (potent vasoconstrictor), increasing levels of plasma renin and reducing aldosterone secretion. Helps control blood pressure and proteinuria. Decreases pulmonary-to-systemic flow ratio in catheterization laboratory and increases systemic blood flow in patients with relatively low pulmonary vascular resistance. Favorable clinical effect when administered over a long period. Helps prevent potassium loss in distal tubules. Body conserves potassium; therefore, less PO potassium supplementation needed.

Patients who develop a cough, angioedema, bronchospasm, or other hypersensitivity reactions after starting ACE inhibitors should receive an angiotensin-receptor blocker.

View full drug information

Captopril (Capoten)

 

Prevents conversion of angiotensin I to angiotensin II (potent vasoconstrictor), lowering aldosterone secretion. Rapidly absorbed, but bioavailability significantly reduced with food intake. Peak concentration in 1 h; has short half-life. Cleared by kidney. Can be started at low dose and uptitrated prn and as patient tolerates.

Impaired renal function requires reduced dosage. Absorbed well PO. Give at least 1 h before meals. If added to water, use within 15 min.

Accepted as essential part of any antifailure therapy; provides symptomatic improvement and prolongs survival.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Christopher C Erickson, MD  Associate Professor, Departments of Pediatrics and Internal Medicine, Electrophysiology and Pacing, University of Nebraska College of Medicine; Associate Clinical Professor, Department of Pediatrics, Creighton University School of Medicine

Christopher C Erickson, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, Cardiac Electrophysiology Society, International Society for Holter and Noninvasive Electrocardiology, and Pediatric and Congenital Electrophysiology Society

Disclosure: Nothing to disclose.

Coauthor(s)

Janice L McAllister, MD  Assistant Professor, Department of Pediatrics, University of Nebraska College of Medicine; Consulting Staff, University of Nebraska Medical Associates, St Joseph Hospital, Children's Hospital of Omaha

Janice L McAllister, MD is a member of the following medical societies: American Academy of Neurology and Child Neurology Society

Disclosure: Nothing to disclose.

Stanley J Radio, MD  Professor, Department of Pathology and Microbiology, University of Nebraska Medical Center

Stanley J Radio, MD is a member of the following medical societies: American Society for Clinical Pathology, American Society of Cytopathology, College of American Pathologists, and International Academy of Pathology

Disclosure: Nothing to disclose.

Specialty Editor Board

James Bowman, MD  Senior Scholar of Maclean Center for Clinical Medical Ethics, Professor Emeritus, Department of Pathology, University of Chicago

James Bowman, MD is a member of the following medical societies: Alpha Omega Alpha, American Society for Clinical Pathology, American Society of Human Genetics, Central Society for Clinical Research, and College of American Pathologists

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

David Flannery, MD, FAAP, FACMG  Vice Chair of Education, Chief, Section of Medical Genetics, Professor, Department of Pediatrics, Medical College of Georgia

David Flannery, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics and American College of Medical Genetics

Disclosure: Nothing to disclose.

Paul D Petry, DO, FACOP, FAAP  Consulting Staff, Freeman Pediatric Care, Freeman Health System

Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Chief Editor

Bruce Buehler, MD  Professor, Department of Pediatrics and Genetics, Director RSA, University of Nebraska Medical Center

Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association

Disclosure: Nothing to disclose.

References

  1. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. Jan 27 2005;352(4):362-72. [Medline].

  2. Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology. Jan 1981;31(1):51-7. [Medline].

  3. Morisawa Y, Fujieda M, Murakami N, et al. Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome. J Neurol Sci. Oct 8 1998;160(2):175-9. [Medline].

  4. Sugie K, Yamamoto A, Murayama K, et ak. Clinicopathological features of genetically confirmed Danon disease. Neurology. Jun 25 2002;58(12):1773-8. [Medline].

  5. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. Aug 15 1995;92(4):785-9. [Medline].

  6. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. Aug 2004;90(8):842-6. [Medline].

  7. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. Aug 24 2000;406(6798):906-10. [Medline].

  8. Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. Sep 13 2005;112(11):1612-7. [Medline].

  9. Riggs JE, Schochet SS, Gutmann L, et al. Lysosomal glycogen storage disease without acid maltase deficiency. Neurology. Jul 1983;33(7):873-7. [Medline].

  10. Byrne E, Dennett X, Crotty B, et al. Dominantly inherited cardioskeletal myopathy with lysosomal glycogen storage and normal acid maltase levels. Brain. Jun 1986;109 (Pt 3):523-36. [Medline].

  11. Lacoste-Collin L, Garcia V, Uro-Coste E, et al. Danon's disease (X-linked vacuolar cardiomyopathy and myopathy): a case with a novel Lamp-2 gene mutation. Neuromuscul Disord. Nov 2002;12(9):882-5. [Medline].

  12. Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. Mar 25 2009;301(12):1253-9. [Medline].

  13. van der Kooi AJ, van Langen IM, Aronica E, van Doorn PA, Wokke JH, Brusse E. Extension of the clinical spectrum of Danon disease. Neurology. Apr 15 2008;70(16):1358-9. [Medline].

  14. Fanin M, Nascimbeni AC, Fulizio L, Spinazzi M, Melacini P, Angelini C. Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol. Apr 2006;168(4):1309-20. [Medline].

  15. Spinazzi M, Fanin M, Melacini P, Nascimbeni AC, Angelini C. Cardioembolic stroke in Danon disease. Clin Genet. Apr 2008;73(4):388-90. [Medline].

  16. Prall FR, Drack A, Taylor M, Ku L, Olson JL, Gregory D. Ophthalmic manifestations of Danon disease. Ophthalmology. Jun 2006;113(6):1010-3. [Medline].

  17. Dworzak F, Casazza F, Mora M, et al. Lysosomal glycogen storage with normal acid maltase: a familial study with successful heart transplant. Neuromuscul Disord. May 1994;4(3):243-7. [Medline].

  18. Laforet P, Charron P, Maisonobe T, et al. Charcot-Marie-Tooth features and maculopathy in a patient with Danon disease. Neurology. Oct 26 2004;63(8):1535. [Medline].

  19. Echaniz-Laguna A, Mohr M, Epailly E, et al. Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease. Muscle Nerve. Mar 2006;33(3):393-7. [Medline].

  20. Froissart R, Maire I. Danon Disease. Orphanet Encyclopedia. 2002;[Full Text].

  21. Konecki DS, Foetisch K, Zimmer KP, Schlotter M, Lichter-Konecki U. An alternatively spliced form of the human lysosome-associated membrane protein-2 gene is expressed in a tissue-specific manner. Biochem Biophys Res Commun. Oct 13 1995;215(2):757-67. [Medline].

  22. Furuta K, Yang XL, Chen JS, Hamilton SR, August JT. Differential expression of the lysosome-associated membrane proteins in normal human tissues. Arch Biochem Biophys. May 1 1999;365(1):75-82. [Medline].

  23. Tachi N, Tachi M, Sasaki K, et al. Glycogen storage disease with normal acid maltase: skeletal and cardiac muscles. Pediatr Neurol. Jan-Feb 1989;5(1):60-3. [Medline].

  24. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. Jun 15 2000;342(24):1778-85. [Medline].

  25. [Guideline] Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. Jan 20 2005;352(3):225-37. [Medline].

  26. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. May 28 2003;289(20):2685-94. [Medline].

  27. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol. Apr 19 2005;45(8):1340-5. [Medline].

  28. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. Jun 8 2004;109(22):2807-16. [Medline].

  29. Stuberg WA. Muscular dystrophy and muscular atrophy. In: Campbell SK, Vander Linden DW, Palisano RJ, eds. Physical Therapy for Children. 3rd ed. Philadelphia, Pa: WB Saunders; 2005:421-52.

  30. Maron BJ, Estes NA 3rd, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. Jun 17 2003;107(23):2872-5. [Medline].

  31. Kashio N, Usuki F, Akamine T, et al. Cardiomyopathy, mental retardation, and autophagic vacuolar myopathy. Abnormal MRI findings in the head. J Neurol Sci. Sep 1991;105(1):1-5. [Medline].

 
Previous
Next
 
Echocardiogram of a patient with Danon disease and severe hypertrophy. The septum is between the arrows. Note the asymmetry between the septum and the posterior wall of the left ventricle. Also see Media files 2-3. Calibration markings are in centimeters. Ao = ascending aorta just above the aortic valve; LV = left ventricle; LVPW = left ventricular posterior wall.
Echocardiogram, short-axis view in diastole, in the same patient as in Media files 1 and 3. Because of the degree of hypertrophy, the cavitary volume is smaller than normal. Calibration markings are in centimeters. Ao = ascending aorta just above the aortic valve; LV = left ventricle; LVPW = left ventricular posterior wall.
Echocardiogram, short-axis view in systole, in the same patient as in Media files 1-2. Note the increased thickening of the septum. Calibration markings are in centimeters. Ao = ascending aorta just above the aortic valve; LV = left ventricle; LVPW = left ventricular posterior wall.
Horizontal ventricular sections of the heart from 16-year-old male adolescent with Danon disease obtained after orthotopic cardiac transplantation. Massive hypertrophy is present (heart weight, 785 g), with diffuse severe fibrosis and marked ventricular dilatation.
Myocyte hypertrophy and vacuolization with interstitial fibrosis in the myocardium of a heart removed during cardiac transplantation (periodic acid-Schiff [PAS] stain; original magnification, X400).
Electron photomicrograph shows autophagic vacuoles with glycogen in a heart removed during cardiac transplantation (uranyl acetate and Reynolds lead citrate; original magnification X20,000).
Electron photomicrograph shows increased amounts of intermyofibrillar glycogen in the myocardium (uranyl acetate and Reynolds lead citrate; original magnification, X13,000).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.